The federal court overseeing thousands of testosterone treatment lawsuits has decided to extend the litigation’s AndroGel bellwether trial schedule by six weeks. The first cases will likely begin going before juries in the summer of 2017.

More than 5,200 testosterone lawsuits are currently pending in the U.S. District Court, Northern District of Illinois, where product liability cases involving AndroGel, Testim and other prescription low-T therapies have been centralized for pretrial proceedings. All of the complaints were filed on behalf of men who suffered heart attacks, strokes and other cardiovascular side effects allegedly related to their use of the medications.

Testosterone Court Rules Out Further Extensions

The federal court currently has plans to convene two sets of bellwether trials, one involving AndroGel lawsuits and the second for the other medications involved in the litigation. AndroGel bellwether trials were slated to begin in the spring of 2017. However, in April, the defense asked that the trial schedule be extended by several months, and asserted that more time was needed to produce certain documents and testimony. In an Order dated April 22nd, the Court agreed to extend the schedule – but only by six weeks.

“At this point, the Court is concerned about, among other things, the impact on the remainder of the MDL proceeding and on coordination with state court litigation that would result from an extension of the length proposed by AbbVie,” the Order stated “The Court also notes that it has, as of yesterday’s date, excluded six cases from the AbbVie bellwether pool, which represents nearly twenty percent of the pool. This will significantly reduce the discovery burden on both sides.”

The Order also stipulated that no other extensions will be granted, barring some unforeseen circumstance.

Bellwether trials are an important aspect of large, multidistrict litigations such as the federal testosterone proceeding. The outcomes of these trials could provide some insight into how juries might rule in similar AndroGel lawsuits.

Obtain Legal Help after a Testosterone Heart Attack

Bernstein Liebhard LLP provides legal assistance to individuals who may have suffered a testosterone-related heart attack, blood clot or stroke. To learn more about the ongoing testosterone litigation, please call 877-779-1414.

Published May 3, 2016 by